Categories: News

Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference. Details are as follows:

Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
Date: Thursday, June 10
Time: 3:00 PM ET

A live webcast of the virtual fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. An archived replay will be available for approximately 30 days following the fireside chat.

About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx™ Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

CONTACT: Investor Contact:
Christopher Taylor
VP, Investor Relations and Corporate Communications
T: 617-949-4220
E: investor@codiakbio.com

Media Contact:
Lindy Devereux
Scient PR
T: 646-515-5730
E: media@codiakbio.com

Staff

Recent Posts

BioHarvest Launches VINIA SuperFood Functional Tea Line

Incremental Product Launch Addresses $3.3 Billion North American Functional Tea Market Opportunity with First SuperFood…

28 minutes ago

Neurotech Innovator UNEEG Medical Receives FDA Breakthrough Device Designation Within Monitoring and Diagnostic of Epilepsy

The designation is a result of UNEEG's strong focus on developing novel disease management support…

28 minutes ago

Lexaria’s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC /…

28 minutes ago

S4 Medical Receives FDA 510(k) Approval for its Redesigned Esophageal Deviation Device and Begins Commercialization

CHAGRIN FALLS, OH / ACCESSWIRE / November 25, 2024 / S4 Medical Corp, an Ohio…

28 minutes ago

Acreage Provides Update on Corporate Transactions

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Acreage Holdings, Inc. ("Acreage" or…

28 minutes ago